The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [70]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Survival Analysis Techniques for Censored and Truncated Data
Rao, M. B., Klein, J. P., & Moeschberger, M. L. (1998) · Technometrics · doi:10.2307/1270658 · Cited by 3,617
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,010
Uppaluri, R., Campbell, K. M., Egloff, A. M., Zolkind, P., Skidmore, Z. L., Nussenbaum, B. A., Paniello, R. C., Rich, J. T., Jackson, R. S., Pipkorn, P. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1695 · Cited by 391
Self-citationde Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 384
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
Adelstein, D., Gillison, M. L., Pfister, D., Spencer, S., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J., Cmelak, A., et al. (2017) · The Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0101 · Cited by 340
Self-citationNeoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y., Catalano, P. J., Lako, A., Ciantra, Z. B., Weirather, J. L., Criscitiello, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2955 · Cited by 371
Self-citationRuffin, A. T., Cillo, A. R., Tabib, T., Liu, A., Onkar, S., Kunning, S. R., Lampenfeld, C., Atiya, H. I., Abécassis, I., Kürten, C. H. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23355-x · Cited by 377
Self-citationImplications of the tumor immune microenvironment for staging and therapeutics
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.156 · Cited by 363
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 366
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Wang, F., Wei, X., Feng, J., Li, Q., Xu, N., Hu, X., Liao, W., Jiang, Y., Lin, X., Zhang, Q., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02712 · Cited by 360
Rotte, A., Jin, J., & Lemaire, V. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 352
Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09976-0 · Cited by 373
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
de Ruiter, E. J., Ooft, M. L., Devriese, L. A., & Willems, S. M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356148 · Cited by 340
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018) · Retina · doi:10.1097/iae.0000000000002181 · Cited by 336
Vos, J. L., Elbers, J. B. W., Krijgsman, O., Traets, J. J. H., Qiao, X., van der Leun, A. M., Lubeck, Y., Seignette, I. M., Smit, L. A., Willems, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26472-9 · Cited by 344
Canning, M. T., Guo, G., Yu, M., Myint, C., Groves, M., Byrd, J. K., & Cui, Y. R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00052 · Cited by 342
Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T., Grimm, M., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 334
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Verma, V., Sprave, T., Haque, W. M., Simone, C. B., Chang, J. Y., Welsh, J. W., & Thomas, C. R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0442-7 · Cited by 320
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 381
Menk, A. V., Scharping, N. E., Rivadeneira, D. B., Calderon, M. J., Watson, M. J., Dunstane, D., Watkins, S. C., & Delgoffe, G. M. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171068 · Cited by 322
Boku, N., Ryu, M., Kato, K., Chung, H. C., Minashi, K., Lee, K.-W., Cho, H., Kang, W. K., Komatsu, Y., Tsuda, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy540 · Cited by 316
Siu, L. L., Even, C., Mesı́a, R., Remenár, É., Daste, A., Delord, J., Krauß, J., Saba, N. F., Nabell, L. M., Ready, N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4628 · Cited by 312
Self-citationShayan, G., Srivastava, R. M., Li, J., Schmitt, N. C., Kane, L., & Ferris, R. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 312
Self-citationStevanović, S., Helman, S. R., Wunderlich, J. R., Langhan, M. M., Doran, S. L., Kwong, M. L. M., Somerville, R. P. T., Klebanoff, C. A., Kammula, U. S., Sherry, R. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2722 · Cited by 319
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance
Wang, C., Li, Y., Jia, L., Kim, J. K., Li, J., Deng, P., Zhang, W., Krebsbach, P. H., & Wang, C. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.04.011 · Cited by 314
Immunotherapy for head and neck cancer: Recent advances and future directions
Cramer, J. D., Burtness, B. A., & Ferris, R. L. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104460 · Cited by 316
Self-citationImproving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Ruffin, A. T., Li, H., Vujanovic, L. N., Zandberg, D. P., Ferris, R. L., & Bruno, T. C. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00531-9 · Cited by 326
Self-citationDong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z. G., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 303
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 306
Translational genomics and recent advances in oral squamous cell carcinoma
Chai, A. W. Y., Lim, K. P., & Cheong, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.011 · Cited by 300
Kürten, C. H. L., Kulkarni, A., Cillo, A. R., Santos, P. M. L., Roble, A. K., Onkar, S., Reeder, C., Lang, S., Chen, X., Duvvuri, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27619-4 · Cited by 318
Self-citationZerdes, I., Matikas, A., Bergh, J. C. S., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 305
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 294
Wallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. W. A. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5904 · Cited by 294
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 297
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285
Sun, J., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 292
Sato-Kaneko, F., Yao, S., Ahmadi, A., Zhang, S. S., Hosoya, T., Kaneda, M. M., Varner, J. A., Pu, M., Messer, K. S., Guiducci, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93397 · Cited by 291
The nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 291
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K., Xin, C.-F., Hong, M. H., Ahn, B., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 286
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Antonio Lopez-beltran, B., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Liang Cheng, C., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13010131 · Cited by 285
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Hanna, G. J., Lizotte, P. H., Cavanaugh, M. E., Kuo, F. C., Shivdasani, P., Frieden, A., Chau, N. G., Schoenfeld, J. D., Lorch, J. H., Uppaluri, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98811 · Cited by 281
Self-citationSacco, A. G., Chen, R., Worden, F. P., Wong, D. J. L., Adkins, D. R., Swiecicki, P. L., Chai‐Ho, W., Oppelt, P., Ghosh, D., Bykowski, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00136-4 · Cited by 277
Self-citationHallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma
Sasahira, T., & Kirita, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082413 · Cited by 275
Chen, Y., Wang, Y.-Q., Lv, J., Li, Y., Chua, M. L. K., Le, Q., Lee, N., Colevas, A. D., Seiwert, T. Y., Hayes, D. N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy470 · Cited by 275
Self-citationCD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Kagamu, H., Kitano, S., Yamaguchi, O., Yoshimura, K., Horimoto, K., Kitazawa, M., Fukui, K., Shiono, A., Mouri, A., Nishihara, F., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0574 · Cited by 256
Zandberg, D., Algazi, A., Jimeno, A., Good, J., Fayette, J., Bouganim, N., Ready, N., Clement, P., Even, C., Jang, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.015 · Cited by 246
Self-citationAdvances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Chen, Y., Li, Z., Zhou, G., & Sun, Y. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2166 · Cited by 269
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Yau, T. C. C., Hsu, C., Kim, T., Choo, S.-P., Kang, Y., Hou, M., Numata, K., Yeo, W., Chopra, A., Ikeda, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.014 · Cited by 267
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Patterns of Response and Progression to Immunotherapy
Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 267
FDG PET/CT for assessing tumour response to immunotherapy
Aide, N., Hicks, R. J., Tourneau, C. L., Lheureux, S., Fanti, S., & Lopci, E. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 266
Oliva, M., Spreafico, A., Taberna, M., Alemany, L., Coburn, B. A., Mesı́a, R., & Siu, L. L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy507 · Cited by 265
Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
Mei, Z., Huang, J., Qiao, B., & Lam, A. K.-Y. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0084-8 · Cited by 268
Walker, M. D., & Shane, E. J. (2022) · JAMA · doi:10.1001/jama.2022.18331 · Cited by 262
Machiels, J., Tao, Y., Licitra, L. F., Burtness, B. A., Tahara, M., Rischin, D., Alves, G. V., Lima, I. P. F., Hughes, B. G. M., Pointreau, Y., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00100-1 · Cited by 264
Self-citationNazha, B., Mishra, M. K., Pentz, R. D., & Owonikoko, T. K. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100021 · Cited by 264
Mechanism of interaction between autophagy and apoptosis in cancer
Das, S., Shukla, N., Singh, S. S., Kushwaha, S., & Shrivastava, R. (2021) · APOPTOSIS · doi:10.1007/s10495-021-01687-9 · Cited by 269
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 291
Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer
Bakst, R. L., Glastonbury, C. M., Parvathaneni, U., Katabi, N., Hu, K. S., & Yom, S. S. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.12.009 · Cited by 257
Biomarkers for immunotherapy response in head and neck cancer
Gavrielatou, N., Doumas, S., Economopoulou, P., Foukas, P. G., & Psyrri, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101977 · Cited by 256
Kitamura, N., Sento, S., Yoshizawa, Y., Sasabe, E., Kudo, Y., & Yamamoto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010240 · Cited by 269
Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255
Rini, B. I., Battle, D. J., Figlin, R. A., George, D. J., Hammers, H. J., Hutson, T., Jonasch, E. W., Joseph, R. W., McDermott, D. F., Motzer, R. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0813-8 · Cited by 259
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273
Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.010 · Cited by 250
Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 254
Kansy, B., Concha‐Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y. L., Moskovitz, J. M., Moy, J. D., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 258
Self-citationHead and neck cancer: improving outcomes with a multidisciplinary approach
Nigro, C. L., Denaro, N., Merlotti, A. M., & Merlano, M. C. (2017) · Cancer Management and Research · doi:10.2147/cmar.s115761 · Cited by 256
Li, Q., Liu, X., Wang, D., Wang, Y., Lu, H., Wen, S., Fang, J., Cheng, B., & Wang, Z. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-00092-3 · Cited by 254
Zhao, X., Suryawanshi, S., Hruska, M. W., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx235 · Cited by 250
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Monge, R. M., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 250
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 261
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Sun, L., Clavijo, P. E., Robbins, Y. L., Patel, P., Friedman, J., Greene, S., Das, R., Silvin, C., Waes, C. V., Horn, L. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126853 · Cited by 239
Immune checkpoints in the tumor microenvironment
Toor, S. M., Nair, V. S., Decock, J. V., & Elkord, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 242
Bigot, F., Álvarez, E. C., Baldini, C., Hollebecque, A., Carmona‐Bayonas, A., Postel-Vinay, S. C., Angevin, E., Armand, J., Ribrag, V., Aspeslagh, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.027 · Cited by 246
Chen, Y., Zhang, Y. X., Lv, J.-W., Li, Y.-Q., Wang, Y., He, Q.-M., Yang, X.-J., Sun, Y. H., Mao, Y., Yun, J., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 234
Ferris, R. L., Spanos, W. C., Leidner, R. S., Gonçalvès, A., Martens, U. M., Kyi, C., Sharfman, W. H., Chung, C. H., Devriese, L. A., Gauthier, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002568 · Cited by 247
Self-citationTreating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Bhatia, A. K., & Burtness, B. A. (2023) · Drugs · doi:10.1007/s40265-023-01835-2 · Cited by 254
Chen, L., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yeh, K., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-01034-7 · Cited by 227
Moik, F., Chan, W.-S. E., Wiedemann, S., Höeller, C., Tuchmann, F., Aretin, M., Fuereder, T., Zöchbauer‐Müller, S., Preusser, M., Pabinger, I., et al. (2020) · Blood · doi:10.1182/blood.2020007878 · Cited by 235
Burtness, B. A., Rischin, D., Greil, R., Soulières, D., Tahara, M., de Castro, G., Jr., Psyrri, A. K., Braña, I., Basté, N., Neupane, P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02198 · Cited by 231
Self-citationGorris, M. A. J., Halilović, A., Rabold, K., van Duffelen, A., Wickramasinghe, I. N. A., Verweij, D. I., Wortel, I. M. N., Textor, J. C., de Vries, I. J. M., & Figdor, C. G. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701262 · Cited by 225
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
(2016) · BDJ · doi:10.1038/sj.bdj.2016.860 · Cited by 221
Keenan, B. P., Fong, L. H., & Kelley, R. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0749-z · Cited by 220
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
Patil, V., Noronha, V., Menon, N. S., Rai, R., Bhattacharjee, A., Singh, A. K., Nawale, K. P., Jogdhankar, S., Tambe, R., Dhumal, S. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01015 · Cited by 221
Soulières, D., Faivre, S. J., Mesı́a, R., Remenár, É., Li, S.-H., Karpenko, A., Dechaphunkul, A., Ochsenreither, S., Kiss, L. A., Lin, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30064-5 · Cited by 219
Self-citationEfficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218
Hepatocellular carcinoma in the era of immunotherapy
Sim, H., & Knox, J. J. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.10.007 · Cited by 216
Wang, D. Y., Ye, F., Zhao, S., & Johnson, D. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344805 · Cited by 220
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221
Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., Tabernero, J. M., Reardon, D. A., Massard, C., Minchom, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00275-9 · Cited by 217
Regulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 218
Wise-Draper, T. M., Gulati, S., Palackdharry, S. M., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N., Kaczmar, J. M., Patil, Y., Riaz, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3351 · Cited by 227
Self-citationOsta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 208
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 213
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1856-1867
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5564292
- OpenAlex
- W2529484692
- Cited by
- 5,101
- References
- 26
- Citations by year
- 2026: 358 · 2025: 461 · 2024: 500 · 2023: 490 · 2022: 574 · 2021: 687 · 2020: 617 · 2019: 543 · 2018: 486 · 2017: 358 · 2016: 17
- FWCI
- 452.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Ono Pharmaceutical
- National Cancer Institute (P50CA097190, R01CA206517)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- nivolumab, PD-1 inhibitors, immune checkpoint inhibitors, platinum-refractory disease, overall survival, progression-free survival, objective response rate, quality of life, treatment-related adverse events, cetuximab, docetaxel, methotrexate, single-agent chemotherapy, metastatic head and neck cancer, immunotherapy
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
